BioCentury
ARTICLE | Product Development

Failing in master protocol casts fresh doubt on hydroxychloroquine even as WHO restarts trial

June 6, 2020 12:18 AM UTC

Capping a fortnight’s worth of roller-coastering hydroxychloroquine news, a June 4 interim analysis of the University of Oxford’s RECOVERY study found that the malaria drug failed to benefit hospitalized COVID-19 patients. It is the most definitive readout of hydroxychloroquine in the indication to date.

Based on the review of the unblinded data, the investigators said Friday that they immediately stopped enrollment in RECOVERY’s hydroxychloroquine arm. ...

BCIQ Company Profiles

University of Oxford